CombiMatrix targets avian flu markets in Asia with Cold Spring Biotech deal:
This article was originally published in Clinica
Executive Summary
CombiMatrix, a division of Acacia Research, has appointed Cold Spring Biotech as non-exclusive distributor of its range of CustomArrays and CatalogArrays in China, Taiwan and Hong Kong. The agreement gives CombiMatrix entry into the fast-growing Asian markets where tests such as the company's Influenza A research microarrays can be used in fighting the spread of influenza H5N1, also known as avian flu.
You may also be interested in...
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.